Lugui Qiu

Lugui Qiu is the leading hematology-oncologist in China for B-cell malignancies and led the pivotal ALPINE trial demonstrating superiority of zanubrutinib over ibrutinib in CLL/SLL. This landmark head-to-head trial established zanubrutinib as a best-in-class BTK inhibitor with improved efficacy and better cardiovascular tolerability. His research program at the Blood Disease Hospital encompasses the full spectrum of lymphoid malignancies with particular expertise in Chinese patient populations. He has trained numerous investigators and fostered international collaborations.